Related Experiment Video
Updated: Jul 15, 2026

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog
Published on: November 5, 2014
Discovery of 6-ethyl-2,4-diaminopyrimidine-based small molecule renin inhibitors
Daniel D Holsworth1, Mehran Jalaie, Thomas Belliotti
1Pfizer Global Research and Development, Michigan Laboratories, 2800 Plymouth Road, Ann Arbor, MI 48105, USA. Daniel.Holsworth@pfizer.com <Daniel.Holsworth@pfizer.com>
Abstract:
Novel 2,4-diaminopyrimidine-based small molecule renin inhibitors are disclosed. Through high throughput screening, parallel synthesis, X-ray crystallography, and structure based drug design, we have developed the first non-chiral, non-peptidic, small molecular template to possess moderate potency against renin. The designed compounds consist of a novel 6-ethyl-5-(1,2,3,4-tetrahydroquinolin-7-yl)pyrimidine-2,4-diamine ring system that exhibit moderate potency (IC(50): 91-650 nM) against renin while remaining 'Rule-of-five' compliant.
Related Concept Videos
Antihypertensive Drugs: Direct Renin Inhibitors
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Renal Drug Excretion: Tubular Secretion
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Dipeptidyl Peptidase 4 Inhibitors
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

